Business Context and Reporting Period
This Form 8-K Current Report, filed on June 13, 2024, covers events occurring on June 11, 2024, regarding Humacyte, Inc.'s 2024 Annual Meeting of Stockholders. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
At the Annual Meeting, 70,031,441 shares (approximately 58.8% of outstanding shares) were present, constituting a quorum. Stockholders voted on two proposals:
- Proposal 1 – Election of Directors: All six Class III director nominees were elected. Following the election, the Board rebalanced director classes by moving John P. Bamforth and Keith Anthony Jones from Class III (expiring 2027) to Class II (expiring 2026). This was achieved through their resignation and immediate re-appointment to ensure equal class membership.
- Proposal 2 – Ratification of Auditors: Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the stockholder vote and the subsequent administrative adjustment to the Board structure.
Investor Verification Checklist
- Verify the updated composition of the Board of Directors, specifically the terms for John P. Bamforth and Keith Anthony Jones as Class II directors.
- Confirm the ratification of PricewaterhouseCoopers LLP for the 2024 fiscal year.
- Review the definitive proxy statement (Schedule 14A) filed on April 29, 2024, for detailed background on the director nominees and auditor selection.